- Lobbying
- Lobbying by AiPharma Global Holdings Limited
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Mark Pryor | United States Senator |
Emily Felder | Director of the Office of Legislation, CMS; Counsel, House Energy and Commerce Committee; Counsel, Senate Committee on Homeland Security and Government Affairs; Counsel, House Oversight and Government Reform Committee |
David Cohen | Prof. Staff-House Comm on Banking & Fin Svcs |
Laura Johnson | Legislative intern - Senate HELP Committee |
Adam Steinmetz | n/a |
Andrew Littman | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
White House Office
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Health & Human Services - Dept of (HHS)
Natl Institutes of Health (NIH)
White House Office
Type of Issue
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: Issues related to the pharmaceutical supply chain.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate